19:29 , Jan 17, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Breast cancer Patient sample and cell culture studies suggest IFNB1 could help treat breast cancer. In breast tissue samples from patients with invasive ductal carcinoma, levels of IFNB1 were higher in tumors than in...
07:00 , Sep 3, 2007 |  BC Week In Review  |  Company News

Bolder BioTechnology, National Institutes of Health autoimmune news

Bolder received a $685,984 Phase II SBIR grant from NIH's National Institute of Arthritis and Musculoskeletal and Skin Diseases to conduct preclinical studies of a pegylated VEGF receptor in disease models of rheumatoid arthritis (RA)....
08:00 , Jan 17, 2005 |  BC Week In Review  |  Company News

Bolder BioTechnology other research news

Bolder announced that National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $500,000 Phase I SBIR grant to optimize the manufacturing process and perform preclinical toxicology and pharmacology studies of erythropoiesis-stimulating protein...
08:00 , Jan 17, 2005 |  BC Week In Review  |  Company News

Bolder BioTechnology other research news

Bolder announced that National Institute of Allergy and Infectious Diseases (NIAID) awarded a $303,204 Phase I SBIR grant to be used to optimize the manufacturing process and perform preclinical toxicology and pharmacology studies of the...